AI and Genomics Are Starting to Rewire Prostate Cancer Care
UroToday explores how AI and genomics are converging to change prostate cancer management, from risk stratification to treatment selection. The shift matters because prostate cancer care is increasingly about matching the right intensity of treatment to the biology of the disease, not just the presence of a tumor.
Prostate cancer has become one of the clearest examples of precision oncology moving into everyday care. AI is adding another layer to that shift by helping interpret complex genomic, imaging, and clinical data that would be difficult to synthesize consistently by hand.
The practical value lies in risk stratification. Many prostate cancers are indolent, while others are aggressive and need timely intervention. Tools that combine AI with genomics may help distinguish those two groups more accurately, reducing overtreatment for some patients and escalating care for others.
This matters because the downside of imprecision is already well known. Too much treatment can damage quality of life, while too little can allow aggressive disease to progress. AI does not solve that tension on its own, but it can make the tradeoffs more evidence-based and more personalized.
The broader implication is that cancer care is becoming less organ-specific and more information-rich. Prostate oncology is a likely early winner because it already uses biomarkers and molecular data heavily. If AI meaningfully improves how those data are interpreted, it could become a model for other solid tumors as well.